Mendus – executive interview

Mendus is a clinical-stage immuno-oncology company focused on haematological and solid cancers. The company is entering an exciting stage of development, with lead asset vididencel soon to be tested with oral azacitidine, the current standard of care in acute myeloid leukaemia (AML) maintenance, in the Phase II CADENCE trial (backed by the prestigious Australasian Leukaemia and Lymphoma Group). Also, preparations are underway for a global registrational trial from late-2025. Following a strategic repositioning, Mendus’s second asset, ilixadencel, is set to re-enter the clinic as part of a basket combination study with regorafenib (a tyrosine kinase inhibitor; Bayer) and avelumab (an immune checkpoint inhibitor; Merck). The initial target will be soft tissue sarcomas, an indication otherwise non-responsive to current immunotherapies.

Recently disclosed immunomonitoring data from the ADVANCE II trial (testing vididencel as a monotherapy maintenance treatment in AML; currently in the long-term follow-up stage) has indicated a broad immune response to the treatment (both T-cell and B-cell), indicative of sustained clinical benefits as a maintenance therapy, and encouraging for subsequent clinical development activities. With H224 expected to be an active period for Mendus involving further data readouts, and commencement of patient recruitment in the CADENCE trial, there is a lot for investors to look forward to.

In this video, we discuss with Mendus’s CEO Erik Manting the company’s exciting recent developments and future plans as it edges closer to the later stages of clinical development.